TQB2916
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research[1].
Product Specifications
UNSPSC
12352203
Target
TNF Receptor
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Ba Y, et al. Abstract CT192: A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies[J]. Cancer Research, 2024, 84 (7_Supplement) : CT192-CT192.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
TNFRSF5/CD40
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
50610065 1.0 µg DNA
YIF1B Lentiviral Vector (Mouse) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details 